Global Infectious Disease Drug Market - Industry Trends & Forecast to 2026

  • Pharmaceutical
  • Upcoming Report
  • Jul 2019
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Infectious Disease Drug Market By Source Type (Bacterial Diseases, Virusal Diseases, Fungal Disease and Parasitic Disease), By Disease Type (Jaundice, Leprosy, Listeria, Lyme disease, Malaria, Measles, Molluscum contagiosum, Molluscum contagiosum, Norovirus, Pyelonephritis, Rabies, Severe acute respiratory syndrome, Sepsis, Tetanus, West Nile, Zika, Ebola disease and Others) By Treatment Type (Medication, Dietary supplements and surgery), By Mode of Action Type (Antibacterial drugs, Antiviral drugs, Antifungal drugs, Antiparasitic drugs ), By Drug Type (Tafenoquine, Omadacycline, Tecovirimat, Eravacycline, Delafloxacin, Plazomicin, Benznidazole, Secnidazole, Daclatasvir, Dalbavancin and Others), By Route of Administration (Oral, Topical and intravenous), By End- users (Hospitals, Homecare, Specialty Clinics, Others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa)  - Industry Trends & Forecast to 2026

Market Analysis: Global Infectious Disease Drug Market

Global infectious disease drugs market is rise gradually to an estimated value of USD 72.49 Billion by 2026 registering a CAGR of 5.5% in the forecast period of 2019-2026 with the annual sales of USD 47.24 billion in the year 2018. This significant rise in market value can increases research development initiatives to launching novel therapies.

Market Definition: Global Infectious Disease Drug Market

Infectious disease is defined as pathogenic microorganism disease caused by infectious agent such as bacteria, viruses, fungi and parasites. It can spread from one person to another healthy individual. People who have likely to developed weakened immune system, this could be due to drugs, age, or other diseases and people who they have not been vaccinated before are prone to the infections.

According to the article published in our World in Data 2016, the global burden of infectious disease was responsible for 10.0 % of causes of death in the world. It is identified that over 229.96 million patients affected with diarrhea and infectious disease. Increases of cases of prevalence rate, Advances in nutrition, antibiotics and immunization. Accelerate demanding of novel therapies and newer developments in diagnostic devices and Government initiatives in sanitization and regulations for food safety are the drivers for market growth.

Market Drivers

  • Increases of cases of prevalence rate of infectious diseases worldwide
  • Advances in nutrition, antibiotics and immunization
  • Accelerate demanding of novel therapies and newer development in diagnostic devices
  • Rising awareness about treatment and technological advancement is driving the growth of market
  • Prevalence of indoor as well as outdoor infections
  • Government initiatives programs in sanitization and regulations for food safety

Market Restraints

  • Effective treatment is either unavailable or unaffordable.
  • Patent expiry from many companies and introduction of generic drugs is expected to restrain the growth if the market.
  • Lack of awareness among the patient and physician about asthma disease treatment.

Segmentation: Global Infectious Disease Drug Market

By Source Type

  • Bacterial Diseases
  • Viruses Diseases
  • Fungus Disease
  • Parasites Disease

By Disease Type

  • Jaundice
  • Leprosy
  • Listeria
  • Lyme disease
  • Malaria
  • Measles
  • Molluscum contagiosum
  • Norovirus
  • Pyelonephritis
  • Rabies
  • Severe acute respiratory syndrome
  • Sepsis
  • Tetanus
  • West Nile
  • Zika
  • Ebola disease
  • Others

By Treatment

  • Medication
  • Dietary supplements
  • Surgery

By Route of administration

  • Oral
  • Topical
  • Injectable

 By End users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

By Geography

  • North America

    • U.S.
    • Canada
    • Mexico

  • South America

    • Brazil
    • Argentina
    • Rest of South America

  • Europe

    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Russia
    • Turkey
    • Belgium
    • Netherlands
    • Switzerland
    • Rest of Europe

  • Asia-Pacific

    • Japan
    • China
    • South Korea
    • India
    • Australia
    • Singapore
    • Thailand
    • Malaysia
    • Indonesia
    • Philippines
    • Rest of Asia Pacific

  • Middle East & Africa

    • South Africa
    • Egypt
    • Saudi Arabia
    • United Arab Emirates
    • Israel
    • Rest of Middle East & Africa

Key Developments in the Market:

On 01 May 2019, Sanofi S.A received FDA approval for Dengvaxia (Dengue Tetravalent Vaccine, Live) for the prophylaxes of dengue disease caused by dengue virus serotypes (1, 2, 3 and 4) in patient upto 9 years old. Dengvaxia also received European Commission approval for treatment of Dengue fever in European endemic areas.

On 8 April 2019, ViiV Healthcare group of companies received FDA approval for Dovato (dolutegravir and lamivudine), a fixed dose combination for the treatment of HIV-infected adults patients who have never treated by any antiretroviral drugs.

0n 13 Feb 2019, Novartis AG received the FDA approval for Egaten (triclabendazole) for the treatment of liver flukes specifically caused by fascioliasis and paragonimiasis. WHO recognized Egaten in an essential medicines lists.

Competitive Analysis:

Global  Infectious Disease Drug Market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of Infectious Disease market for global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Key Market Players:

Few of the major competitors currently working in the Infectious Disease market are F. Hoffmann-La Roche Ltd (Switzerland), Gilead Sciences, Inc. (US), GlaxoSmithKline Plc (UK), Johnson & Johnson Services, Inc. (US), Merck & Co., Inc. (US), Pfizer Inc. (US), AbbVie Inc. (US), Vertex Pharmaceuticals Incorporated (US), ViiV Healthcare group of companies (UK), Sanofi S.A (France), Eli Lilly and Company (US) , Novartis AG (Switzerland), Mitsubishi Tanabe Pharma Corporation (Japan) and few among others.

Research Methodology: Global Infectious Disease  Drug Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analysed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Primary Respondents

Demand Side: Doctors, Surgeons, Medical Consultants, Nurses, Hospital Buyers, Group Purchasing Organizations, Associations, Insurers, Medical Payers, Healthcare Authorities, Universities, Technological Writers, Scientists, Promoters, and Investors among others.

Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Reasons to Purchase this Report

  • Current and future of Global  Infectious Disease Drug  Market outlook in the developed and emerging markets
  • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period
  • Regions/Countries that are expected to witness the fastest growth rates during the forecast period
  • The latest developments, market shares, and strategies that are employed by the major market players


SKU-

Please fill in the below form for detailed Table of Content

Please fill in the below form for detailed List of Table

Please fill in the below form for detailed List of Figure

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
BUY NOW ADD TO CART
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19